Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ESRRG | P62508 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.52 |
| ▸ | ESRRB | O95718 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781696 | 0.85 | LMNA (0.70) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL486593 | 0.83 | EPHX2 (0.56) | RAB9ANPC1MAPK1SMN1; SMN2HPGD | |
| SCHEMBL10202491 | 0.81 | RAB9A (0.62) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL15942950 | 0.80 | RAB9A (0.65) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL14370083 | 0.78 | TMEM97 (0.59) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL15320627 | 0.77 | TMEM97 (0.61) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL4692558 | 0.76 | RAB9A (0.63) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL9490980 | 0.76 | SMN1; SMN2 (0.73) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL5696345 | 0.76 | RAB9A (0.68) | RAB9ANPC1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL14615882 | 0.76 | RAB9A (0.68) | RAB9ANPC1MAPK1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9034372-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8962015-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | RAB9A 2919/4885NPC1 228/4885MAPK1 4605/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | RAB9A 4107/4885NPC1 358/4885MAPK1 4111/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | RAB9A 1904/4885NPC1 90/4885MAPK1 4823/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | RAB9A 2062/4885NPC1 75/4885MAPK1 4528/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | RAB9A 1424/4885NPC1 43/4885MAPK1 4854/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | RAB9A 2919/4885NPC1 228/4885MAPK1 4605/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | RAB9A 2919/4885NPC1 228/4885MAPK1 4605/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | RAB9A 1504/4885NPC1 234/4885MAPK1 3292/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | RAB9A 4475/4885NPC1 231/4885MAPK1 3993/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | RAB9A 2062/4885NPC1 75/4885MAPK1 4528/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | RAB9A 2062/4885NPC1 75/4885MAPK1 4528/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | RAB9A 1424/4885NPC1 43/4885MAPK1 4854/4885 |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | RAB9A 2062/4885NPC1 75/4885MAPK1 4528/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | RAB9A 2939/4885NPC1 347/4885MAPK1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.